Akesos NGF Monoclonal Antibody (AK115) Approved To Initiate Clinical Trial In Pain (Including Cancer Pain)

CytoReason, a leading developer of computational disease models for efficient drug discovery and development, today announced the extension of its collaboration agreement with Pfizer. The extension of our collaboration with CytoReason will build upon our existing data science capabilities, and further enhance our ability to make data-driven decisions across our portfolio," said Mikael Dolsten, M.D., Ph.D., Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer. "We are excited to continue this successful partnership, which has helped us investigate challenging biological questions to potentially inform the development of new therapies for the benefit of patients." CytoReason has established itself as a global leader in computational modeling of human diseases. The company's multidisciplinary team of 65 leading biologists, bioinformaticians and data engineers has developed a technology that enables pharma and biotech companies to speed up drug R&D and bring novel therapies to the patients who most need them. Since launching the collaboration in 2019, Pfizer has used CytoReason's models in Pfizer's research to enhance the understanding of the immune system in pursuit of developing innovative drugs. CytoReason's platform has provided Pfizer with multiple insights in a number of R&D programs across over 20 diseases. "It's exciting to see our technology in the hands of such a stellar group of scientists," said David Harel, CytoReason's CEO and Co-founder. "Our work with the Pfizer team has demonstrated how our computational models can potentially match the right treatment to the right patient groups, across multiple therapeutic areas. Through this collaboration and our growing customer base worldwide, we aim to establish our platform as the gold standard for drug discovery, development and portfolio management." About CytoReason CytoReason is a leading technology company developing computational disease models. The company collects proprietary data from pharmaceutical companies and uses it to simulate human diseases

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!